Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

A novel direct-acting antiviral against Influenza A virus

Summation

  • “This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic.
  • , a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND) application from the U.
  • Due to VNT-101’s novel mechanism of action, it has also demonstrated activity in vitro against influenza A strains harboring resistance mutations to currently available influenza therapeutics.

Via Nova Therapeutics, Inc., a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its Influenza A nucleoprotein inhibitor, VNT-101.

“We look forward to evaluating VNT-101 in the clinic,” said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. “This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic.”

About the VNT-101 program
VNT-101 is a novel investigational small molecule being developed for treatment of seasonal influenza A infection. It is directed against a novel target, the influenza A nucleoprotein (NP). VNT-101 has demonstrated activity in vitro against seasonal influenza A and highly pathogenic avian influenza (HPAI) H5N1 and H7N9 strains. Due to VNT-101’s novel mechanism of action, it has also demonstrated activity in vitro against influenza A strains harboring resistance mutations to currently available influenza therapeutics.

Other FDA News of Interest

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy